The withdrawal of drugs for commercial reasons: the incomplete story of tositumomab.
Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
Vinay
V
Prasad
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D017327:Clinical Trials, Phase IV as Topic; D003132:Commerce; D017277:Drug Approval; D004345:Drug Industry / Q000191:economics*; D011307:Drug Prescriptions / Q000706:statistics & numerical data*; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000401:mortality; D012008:Recurrence; D000069283:Rituximab; D016019:Survival Analysis; D017211:Treatment Failure; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; C119496:tositumomab I-131